Hims & Hers shares drop after US FDA warns of misleading weight‑loss drug claims

** Shares of telehealth platform Hims & Hers Health HIMS.N fall 7.1% to $50.11

** The U.S. Food and Drug Administration has sent a warning letter to HIMS regarding its compounded versions of Novo Nordisk's NOVOb.CO diabetes drug Ozempic and weight-loss treatment Wegovy

** "Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not," the FDA says in the letter

** As of last close, HIMS stock was up 106.5% YTD